Articles

Results from an open-label, randomized phase 3 trial evaluating the effects of panitumumab plus best supportive care versus best supportive care alone in chemorefractory, wild-type KRAS exon 2 and wild-type RAS metastatic colorectal cancer. Read More ›

Results from a phase 1b study of the anticancer stem-cell agent demcizumab plus gemcitabine with or without nab-paclitaxel in the first-line treatment of patients with pancreatic cancer. Read More ›

Results from a phase 1b study of the cancer stem-cell pathway inhibitor BBI608 plus gemcitabine and nab-paclitaxel in treating patients with metastatic pancreatic ductal adenocarcinoma. Read More ›

Results of a clinical trial to determine if transcatheter chemoembolization, radiofrequency ablation, and cryoablation can enhance the effect of the CTLA-4 inhibitor tremelimumab in treating patients with hepatocellular carcinoma or biliary tract carcinoma. Read More ›

Safety and efficacy results of a phase 2 trial assessing outcomes of patients with resected pancreatic adenocarcinoma treated with gemcitabine plus cisplatin and stratified by tumor excision repair cross-complementing gene-1 (ERCC1). Read More ›

Results of a phase 1b/2 study of the safety and efficacy of the cancer stem-cell inhibitor BBI608 plus paclitaxel in treating patients with advanced pancreatic cancer. Read More ›

Benjamin P. Levy, MD, reviews current and emerging roles for agents that target the VEGF axis in advanced non–small-cell lung cancer and expresses his belief that a lot of work needs to be done to define the optimal space for these drugs. Read More ›

Read More ›

Benjamin P. Levy, MD, provides an overview of evolving strategies to manage patients with acquired TKI resistance in advanced non–small-cell lung cancer with a focus on identifying and treating t790m. Read More ›

Modification of the current treatment regimen of RVD to “RVD-lite” provided better tolerability and enhanced clinical benefits in transplant-ineligible patients and proved to be particularly manageable in older populations, even with a wide variety of performance statuses at the beginning of the study. Read More ›